First-in-Class Bispecific Antibody for R/R Follicular Lymphoma Wins FDA Approval
The FDA granted accelerated approval to the bispecific monoclonal antibody mosunetuzumab…
Browsing Tag
Follicular
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a…
Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment
Bone marrow biopsy (BMB) provided little information for response assessment in clinical trials…
Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma
CHICAGO -- A third-line combination involving a newer-generation Bruton's tyrosine kinase (BTK) inhibitor plus obinutuzumab (Gazyva)…
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2…
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented…
How Parsaclisib Compares to Other PI3K Inhibitors for Follicular Lymphoma
In the phase II CITADEL-203 trial presented at the American Society of Hematology (ASH) annual meeting,…
Tisagenlecleucel Promising in R/R Follicular Lymphoma
Tisagenlecleucel (tisa-cel; Kymriah) produced a high overall response rate and complete response (CR) rate in…
Will Bispecific Antibodies Challenge CAR T-Cell Therapy in Follicular Lymphoma?
Investigational bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy for…
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma
ATLANTA -- Patients with newly diagnosed low-burden follicular lymphoma (FL) in remission avoided chemotherapy significantly…
Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma
ATLANTA -- Use of the investigational bispecific antibody mosunetuzumab achieved deep and durable remissions in previously treated…